Amgen Completes $27.8 billion Acquisition of Horizon Therapeutics
Amgen Completes $27.8 billion Acquisition of Horizon Therapeutics
Amgen has completed its acquisition of Horizon Therapeutics for approximately $27.8 billion. The acquisition was approved by the US Federal Trade Commission (FTC) in early September. Following concessions by Amgen, the authority has dropped its earlier objections to the purchase.
In May, the FTC had opposed the acquisition, arguing that Horizon had a monopoly position with its drugs in the US in the fight against certain diseases. Now, the FTC attaches conditions to its approval: Amgen may not bundle any of its products with Horizon's Tepezza or Krystexxa, nor may it use rebates or contract terms to disadvantage competing products. In addition, Amgen may acquire potential competing products to Horizon drugs only with the FTC's permission.